Heron Therapeutics (HRTX) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$1.9 billion.
- Heron Therapeutics' Retained Earnings fell 70.6% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 70.6%. This contributed to the annual value of -$1.9 billion for FY2024, which is 71.25% down from last year.
- Heron Therapeutics' Retained Earnings amounted to -$1.9 billion in Q3 2025, which was down 70.6% from -$1.9 billion recorded in Q2 2025.
- Heron Therapeutics' 5-year Retained Earnings high stood at -$1.4 billion for Q1 2021, and its period low was -$1.9 billion during Q3 2025.
- Its 5-year average for Retained Earnings is -$1.8 billion, with a median of -$1.9 billion in 2023.
- In the last 5 years, Heron Therapeutics' Retained Earnings plummeted by 1875.96% in 2021 and then fell by 4.85% in 2025.
- Quarter analysis of 5 years shows Heron Therapeutics' Retained Earnings stood at -$1.6 billion in 2021, then decreased by 11.28% to -$1.8 billion in 2022, then fell by 6.16% to -$1.9 billion in 2023, then decreased by 0.71% to -$1.9 billion in 2024, then decreased by 0.9% to -$1.9 billion in 2025.
- Its Retained Earnings stands at -$1.9 billion for Q3 2025, versus -$1.9 billion for Q2 2025 and -$1.9 billion for Q1 2025.